PharmApprove, Leading Regulatory and Scientific Communications Firm, Expands in Europe with Coos De Graaf Named New Head of European Operations

PharmApprove expands their services and geographic reach with an expansion in Europe and the hiring of a new Principal.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Coos F. De Graaf

Coos F. De Graaf named PharmApprove Principal for Commercial Operations in Europe.

“There are tremendous opportunities to extend our expertise in Europe, both in the development and post-approval stages.” - Coos de Graaf, Principal, Commercial Operations in Europe

Lawrenceville, NJ (PRWEB) December 17, 2013

PharmApprove, a division of Taft and Partners, announced today that it has expanded its geographic reach by opening a European Office. Coos De Graaf has joined the firm as Principal, Commercial Operations in Europe, signaling a new push towards expanded services and geographic markets. De Graaf has more than 30 years of experience in the pharmaceutical industry, including numerous roles in senior management.

PharmApprove is a leading strategic, regulatory and scientific communication consultancy to the pharmaceutical and biotechnology industries.

Mr. De Graaf will lead PharmApprove’s efforts to help companies successfully navigate the product approval and value demonstration process throughout Europe. With his leadership, PharmApprove will be able to offer expanded services to clients as they prepare to bring new therapeutic agents and devices before regulatory and health technology assessment agencies.

“PharmApprove has established client experience in Europe, but adding a leader of Coos De Graaf’s caliber positions us extremely well to continue growing to serve our clients globally,” said Laurie Smaldone, M.D., President of PharmApprove. “In addition we are excited to announce expanded services building upon our success in supporting product approvals to include market access communication support.”

Mr. De Graaf led various executive functions at Solvay Pharmaceuticals including global compliance and clinical and commercial development. Other past accomplishments include developing the European presence for the Campbell Alliance .

“I am excited to join PharmApprove, which has a long track record of success working with pharmaceutical and biotechnology companies,” said De Graaf. “There are tremendous opportunities to extend our expertise in Europe, both in the development and post-approval stages.”

Historically, PharmApprove has helped drug developers effectively communicate to regulators and advisory panels in the US and Europe. With the company’s new expansion, it has not only strengthened its European capabilities but fully built out three main pillars of focus:

  •     Advisory Committee Preparation
  •     Regulatory Communication
  •     Market Access Communications Support

PharmApprove has relaunched its web site – http://www.pharmapprove.com -- with full background on its services and Principals.

About PharmApprove:

PharmApprove is the leading strategic, regulatory, and scientific communications consultancy to the pharmaceutical and biotech industries in the US, Canada and Europe. The firm offers both strategic and tactical support to companies facing high-profile, high stakes events and engagements anywhere along the road to approval and commercialization, helping them win health authority approvals, deliver compelling regulatory communications, and make persuasive pharmacoeconomic arguments to payers and HTAs.


Contact